Answers are grounded in this paper and cite their sources.
Examines metabolic effects of erythropoietin in mice lacking receptor in adipose tissue, suggesting therapeutic avenues for obesity and diabetes.
Introduction and Objective: Erythropoietin (EPO) is a glycoprotein cytokine produced primarily by the kidney in a hypoxia dependent manner to regulate erythrocyte production. Viewed as hematopoietic specific to activate the EPO receptor (EPOR) on erythroid progenitor cells, the distribution of EPOR in non-hematopoietic tissue expands EPO activity beyond erythropoiesis, including the potential to regulate adiposity and glucose metabolism. Methods: To assess the metabolic effects of EPO, we used wild-type mice (WT; C57BL/6), and transgenic mice that lack EPOR in adipose tissue (fat EPOR knockout using Adipo-Cre (ΔEPORAdipo) or aP2-Cre (ΔEPORaP2) and erythroid restricted EPOR rescue of EPOR knockout mice (ΔEPORE)). At age 6 months, mice were fed a high-fat diet (HFD; 60% kcal fat) and treated with EPO (3000 U/kg) or saline, 3X per week, for three weeks. Results: Without EPO treatment, WT mice had lower fat mass than the transgenic mice indicating that endogenous EPO signaling regulated fat mass accumulation. With EPO treatment, fat mass accumulation and body weight were further reduced in WT mice, especially in males, compared with saline-treated WT mice and transgenic mice, demonstrating EPO protection against diet-induced obesity (DIO), especially in males, and the protective activity of estrogen from DIO in females. In WT mice, EPO treatment reduced fasting glucose and improved glucose tolerance. Lack of EPOR in adipose tissue impaired glucose tolerance, evidenced by higher fasting and GTT glucose levels in transgenic mice versus EPO-treated WT controls. In transgenic mice, EPO does not improve fasting glucose or glucose tolerance in males with some improvement seen in females. Conclusion: These results highlight EPO regulation of fat mass accumulation and glucose tolerance mediated by EPOR in adipose tissue independent of EPO regulated erythropoiesis. These EPO activities to promote a lean phenotype in mice may inform novel therapeutic strategies for obesity and type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
ROGERS et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: